Special Delivery $19.043M Market Capitalization Lexaria Bioscience Corp. (LEXX.Q) is a biotechnology company developing DehydraTECH™, the Company’s proprietary drug delivery technology. In addition to enhancing the speed and efficiency of…
Search Results for: lexx.q
28 June 2022
Lexaria Bioscience (LEXX.Q) – Three Minute Hits Video
Kieran Robertson- LEXX.Q
Today, Kieran Robertson breaks down what he thinks about Lexaria Bioscience (LEXX.Q), a biotech that has developed a patented drug delivery technology, DehydraTECH, to improve the way active pharmaceutical…
Lexaria Bioscience (LEXX.Q) announced today that its DehydraTECH™ technology has been embraced by consumer brands and is now available for sale in over 7,000 stores across the US. “Lexaria’s…
Lexaria Bioscience (LEXX.Q) announced today that dosing has been completed for its HYPER-H21-2 study, the Company’s second human clinical study of 2021. Hypertension, also known as high blood…
Lexaria Bioscience (LEXX.Q) announced today that its tolerability and pharmacokinetic study VIRAL-A20-3 has been completed with positive results. Read full article here: https://equity.guru/2021/07/lexaria-bioscience-lexx-q-announces-positive-results-for-viral-a20-3-study-shares-climb-66/…
Lexaria Bioscience (LEXX.Q) announced today that its tolerability and pharmacokinetic study VIRAL-A20-3 has been completed with positive results. The VIRAL-A20-3 study was performed using Sprague-Dawley rats, with…
Lexaria Bioscience (LEXX.Q) today announced results from its antiviral drug molecular characterization study VIRAL-MC21-1 recently completed by Canada’s premier federally funded research organization, the National Research Council (NRC). …
Eye Don’t Believe It Fill Disclosure: weekly roundups are intended to provide a quick introduction to various companies. They are not intended to be deep dives or opinion…
Closing the Diabetic Loop Before we get into this week’s sector roundup, let’s talk about diabetes. I am a sucker for sweets, so much so that I was diagnosed…
Smart Watch, Healthy Heart There was an opportunity for a pun in the headline and I took it. In this week’s sector roundup, we are going to be…